{ "schemaVersion": "deck-intelligence.v1", "id": "019de076-f8dc-71cb-8c77-d8d892e68e05", "slug": "d63a60a343bcaadeb9fd5627a42c66c9", "title": "CARGO Therapeutics | IPO Presentation Deck | 29 slides", "subtitle": "CARGO Therapeutics · 2024-03", "author": "CARGO Therapeutics", "date": "2024-03-01 00:00:00", "pageCount": 29, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7794254, "document": { "id": "019de076-f8dc-71cb-8c77-d8d892e68e05", "slug": "d63a60a343bcaadeb9fd5627a42c66c9", "title": "CARGO Therapeutics | IPO Presentation Deck | 29 slides", "rawTitle": "CARGO Therapeutics | IPO Presentation Deck | 29 slides", "authorId": "cargo-therapeutics", "authorName": "CARGO Therapeutics", "authorDisplay": "CARGO Therapeutics", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investment_bank", "label": "Investment bank" }, "fileName": "2024-03__cargo-therapeutics__ipo__d63a60a3.pdf", "sourceUrl": "https://www.slidebook.io/company/cargo-therapeutics/presentation/d63a60a343bcaadeb9fd5627a42c66c9/", "sourceDate": null, "presentationDate": "2024-03-01 00:00:00", "ingestedAt": "2026-04-30 22:16:26.688188+00", "status": "ready", "pageCount": 29, "orientation": "landscape", "aspectRatio": 1.7794254, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2024-03__cargo-therapeutics__ipo__d63a60a3", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "IPO Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 29, "pagesIndexed": 29, "pagesWithImages": 29, "pagesWithMetadata": 29, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 108, "chartCount": 10, "metricSlides": 0, "toolMatches": 6, "documentToolMatches": 0, "frameworkMatches": 8, "arcMatches": 1, "beatMatches": 5, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "cc3a66c0-9acc-46c3-9d21-6e1e6cdc7cce", "evidence": "The deck follows a structure similar to the Sequoia Pitch, with sections on problem, solution, market sizing, traction, and team", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:43:25.879833+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 10, "name": "Problem", "beatId": "a9f20cbe-143f-496d-bc90-e53c6de8c8f4", "matchId": "cc3a66c0-9acc-46c3-9d21-6e1e6cdc7cce", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slide 10 presents the problem statement", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 18, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 18, "name": "Solution", "beatId": "0b7c883f-3725-4066-9502-b130398fca42", "matchId": "cc3a66c0-9acc-46c3-9d21-6e1e6cdc7cce", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slide 18 presents the solution overview", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 9, "name": "Market Size", "beatId": "90b278ba-14fd-46df-ab28-dbf89276c85e", "matchId": "cc3a66c0-9acc-46c3-9d21-6e1e6cdc7cce", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "Slide 9 presents market sizing information", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 15, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 12, "name": "Traction", "beatId": "2e0a910a-dd04-43c7-b080-55652ca53d9d", "matchId": "cc3a66c0-9acc-46c3-9d21-6e1e6cdc7cce", "beatType": null, "evidence": "Slides 12-15 present traction and results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 6, "name": "Team", "beatId": "ad576464-d783-4af6-b425-f8685860a497", "matchId": "cc3a66c0-9acc-46c3-9d21-6e1e6cdc7cce", "beatType": { "name": "Team", "slug": "sequoia-pitch-team", "status": "active", "canonId": "019dd9b8-23c9-746f-aaf9-2f5d83892cf3", "version": 1, "description": null }, "evidence": "Slides 6-7 present team information", "position": 4, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 15, "from": 10, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "1e639289-7657-46f8-9306-fe7898bf6a06", "evidence": "The loop is opened on slide 10 and closed on slides 12-15", "position": 0, "objective": "What is the cost of not addressing the unmet need for LBCL patients whose disease is R/R to CD19 CAR T-cell therapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.138718+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null, "categoryName": "Vision", "categorySlug": "vision" }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "4c842e33-028b-4cff-944e-0c70823f8b29", "evidence": "title/headline: CARGO THERAPEUTICS", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:44:49.161999+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0328cb50-839e-405e-8e0f-ec758dae938c", "evidence": "list/bullet: Positive Phase 1 results in CD19 CAR T R/R LBCL – 53% CR rate (20 of 38 patients) with ongoing durable responses in 85% of CRs (17 of 20) at median follow-up of 23 months; 120+ patients have been dosed; Init", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:44:55.805258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "dc7f75cc-612f-4e02-a3fa-ef61433df054", "evidence": "table/data: Cytokine Release Syndrome and Neurologic Events/ICANS data for DL1, DL2, and Total cohorts compared to ZUMA-1, JULIET, and TRANSCEND.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:45:24.402836+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "bdc83d46-4efb-40ff-972a-fc4639626464", "evidence": "Matrix of therapies by modality (Auto, Allo, Bispecifics) and phase (1, 2, 3, Approved)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:44:53.691873+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "5a6e40f7-9297-435d-8179-e16d50eab4ab", "evidence": "CARGO – focused on developing and delivering potentially curative cell therapies", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:44:53.796678+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Storytelling: the closing ask", "slug": "closing-ask", "status": "active", "bestFor": null, "canonId": "019df269-24e0-70ab-8dd9-983832c1c665", "version": 1, "bodyDocId": "019df269-24bc-7554-b88d-245127606b8d", "description": "The single most important slide in the deck — after the cover. The final", "familyLabel": "narrative-block", "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "agent": "storyteller", "layer": "slide", "agents": [ "storyteller" ], "matchId": "12cfb54e-21c5-4487-bdb7-257c4696e4ad", "evidence": "Thank you", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:44:53.896346+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "d7ac9648-b925-4cca-a37d-d83b84ff4495", "evidence": "Pipeline development stages visualized as horizontal bars over time/phase", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:51.419+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "gantt-chart" }, { "matchId": "62e11845-861c-4c0e-a84a-4a131fb98c5c", "evidence": "Frames the current poor outcome (before) as the problem to be solved by the candidate (after).", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:56.761+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "before-after-framing" }, { "matchId": "efd709a1-b281-443f-93d4-5cc33550958a", "evidence": "Sequential flow of clinical trial stages", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:51.248+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "process" }, { "matchId": "458a23d7-f031-4a5b-956b-0b1593bca8a5", "evidence": "Direct comparison of clinical trial safety data against historical benchmarks for approved therapies.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:51.52+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "frameworkName": "comparison_frame" }, { "matchId": "06ac952f-32e3-4966-af82-492fb6200a7f", "evidence": "Maps strategic principles to operational outcomes", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:51.945+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "frameworkName": "Strategic Alignment Matrix" }, { "matchId": "e12bdec2-c728-4c7a-8157-6f2ac5442592", "evidence": "Table explicitly links resistance mechanisms to technological solutions.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:51.706+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "frameworkName": "problem-solution-mapping" }, { "matchId": "574ea350-b439-431e-a4cc-3a462715cb50", "evidence": "Screening funnel diagram", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:02:51.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "frameworkName": "funnel" }, { "matchId": "3eb4066a-bb9b-4270-9a8e-8c7433cf5973", "evidence": "The slide organizes data into a grid based on modality and clinical phase.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:53.495+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "frameworkName": "matrix-nxn" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/59lzczGJk9Mpw380irilGd064CkOj_tWYk7k7afxzrE/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9kNjNhNjBhMzQzYmNhYWRlYjlmZDU2MjdhNDJjNjZjOS9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 3, "componentCount": 2, "textChars": 18, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:48.374+00", "seconds": 1.948, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/1", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-1", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.35, "x": 0.58, "y": 0.2 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.374+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d378076c-6f14-4c84-8d95-84b8a8a6c6f2", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.45, "x": 0.05, "y": 0.35 }, "kind": "title", "text": "CARGO THERAPEUTICS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.374+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8be972ad-71d3-43e7-af23-e7077119eabf", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "4c842e33-028b-4cff-944e-0c70823f8b29", "evidence": "title/headline: CARGO THERAPEUTICS", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:44:49.161999+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/aFbnIwnb-Jzwlywi6DEHnJAxuBDwzSdhAym96IszCog/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9kNjNhNjBhMzQzYmNhYWRlYjlmZDU2MjdhNDJjNjZjOS9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/uAED9j7stvm_JO9Yun6jBrprmi6qDLY9vZYPHBzv0B8/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9kNjNhNjBhMzQzYmNhYWRlYjlmZDU2MjdhNDJjNjZjOS9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/vTe3_Xr1lm-9O5qN3_Fa0k7dmnGEQfCEhvaySzZeBCY/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9kNjNhNjBhMzQzYmNhYWRlYjlmZDU2MjdhNDJjNjZjOS9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 7, "componentCount": 2, "textChars": 77, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:48.718+00", "seconds": 2.291, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/2", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-2", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.695, "w": 0.904, "x": 0.048, "y": 0.208 }, "kind": "disclaimer", "text": "This presentation has been prepared by CARGO Therapeutics, Inc. ...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.718+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a1e203fb-f163-445d-8254-40993e76cef4", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.135, "x": 0.048, "y": 0.105 }, "kind": "title", "text": "Disclaimer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.718+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3dc01b99-550b-4f45-80e1-6e0b7cbe140b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "setup", "function": "summarize", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 45, "componentCount": 2, "textChars": 836, "nDataPoints": 6, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:51.186+00", "seconds": 4.741, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/3", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-3", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.91, "x": 0.063, "y": 0.205 }, "kind": "table", "text": "Issuer: CARGO Therapeutics, Inc. Exchange / Ticker: Nasdaq / CRGX Base offering size: $300.0 million (18,750,000 shares at midpoint of filing range, prior to option to purchase additional shares) Option to purchase additional shares: 2,812,500 shares (15% of base deal, 100% primary) Filing range: $15.00 - $17.00 per share Use of proceeds: CARGO intends to use the net proceeds from this offering, as follows: to fund its Phase 2 clinical trial of CRG-022 to fund research and development of new product candidates for working capital and other general corporate purposes Bookrunners: J.P. Morgan | Jefferies | TD Cowen | Truist Securities Stabilization agent: J.P. Morgan Expected pricing: Thursday, November 9, 2023 Lock-up: 180 days for company, directors, officers, affiliates and substantially all security holders", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.186+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2c9b5965-7a80-4f82-9b8d-5d9aa9aac084", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.279, "x": 0.047, "y": 0.095 }, "kind": "title", "text": "Offering summary", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.186+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c346871b-2251-436c-960c-3215fdc38462", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 4, "type": "setup", "function": "front_matter", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 23, "componentCount": 4, "textChars": 130, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:49.149+00", "seconds": 2.531, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/4", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-4", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.4, "x": 0.55, "y": 0.2 }, "kind": "image", "text": "3D rendering of a T-cell", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.149+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4115f1f1-cbb6-4d0e-b964-29064ec5a2a9", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.2, "x": 0.05, "y": 0.05 }, "kind": "image", "text": "Cargo Therapeutics logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.149+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5d0144a1-a663-4b15-b4aa-53619ad54d21", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.05, "y": 0.68 }, "kind": "paragraph", "text": "November 2023", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.149+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f5112102-2991-432c-a94b-ca64bf05b118", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.5, "x": 0.05, "y": 0.45 }, "kind": "title", "text": "Engineering Next Generation CAR T-cell Therapies To Deliver More Cures", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.149+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "35f750db-11a7-4244-9811-55f32a24c1dc", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 5, "type": "setup", "title": "The slide uses a chevron-based layout to categorize key company pillars.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 64, "componentCount": 5, "textChars": 674, "nDataPoints": 5, "notes": "The slide uses a chevron-based layout to categorize key company pillars.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:49.461+00", "seconds": 2.808, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/5", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-5", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.7, "x": 0.26, "y": 0.76 }, "kind": "list", "text": "Co-founded in 2021 by globally recognized pioneers; Seasoned, strong leadership team; $200M Series A preferred stock round in February 2023", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.461+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "21b73b8b-2529-486b-8eae-b5026ee856c2", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.7, "x": 0.26, "y": 0.52 }, "kind": "list", "text": "Leveraging proprietary cell engineering platform technologies to develop a pipeline of programs; CRG-023, an IND-enabling stage tri-specific targeting CD19, CD20 and CD22", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.461+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "56de476a-9c81-4d5f-930c-7b08c21cde7a", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.7, "x": 0.26, "y": 0.215 }, "kind": "list", "text": "Positive Phase 1 results in CD19 CAR T R/R LBCL – 53% CR rate (20 of 38 patients) with ongoing durable responses in 85% of CRs (17 of 20) at median follow-up of 23 months; 120+ patients have been dosed; Initiated Phase 2; Stanford granted Breakthrough Therapy Designation", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.461+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9a8d551e-2612-4ae9-b062-0b2d43097275", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.2, "x": 0.04, "y": 0.92 }, "kind": "source-note", "text": "Note: As of May 3, 2023 data cutoff date", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.461+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f4938077-f5f8-4e75-a71e-42f1389c4209", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.04, "y": 0.08 }, "kind": "title", "text": "CARGO – developing potentially curative cell therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:49.461+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6dc504c3-8afa-45d7-aaed-d8d2700f266e", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0328cb50-839e-405e-8e0f-ec758dae938c", "evidence": "list/bullet: Positive Phase 1 results in CD19 CAR T R/R LBCL – 53% CR rate (20 of 38 patients) with ongoing durable responses in 85% of CRs (17 of 20) at median follow-up of 23 months; 120+ patients have been dosed; Init", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:44:55.805258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 6, "type": "setup", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 16, "componentCount": 3, "textChars": 150, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:48.898+00", "seconds": 2.186, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/6", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-6", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.68, "w": 0.906, "x": 0.047, "y": 0.21 }, "kind": "image", "text": "8 individual headshots", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "37b11992-2f35-42a7-bcda-ceb91a025a6d", "parentComponentId": null }, { "bbox": { "h": 0.68, "w": 0.906, "x": 0.047, "y": 0.21 }, "kind": "paragraph", "text": "Names, titles, and company logos for 8 executives.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3b6ec18f-627f-4d1a-8021-0eda0464c0b0", "parentComponentId": null }, { "bbox": { "h": 0.13, "w": 0.65, "x": 0.047, "y": 0.047 }, "kind": "title", "text": "Seasoned leadership team with significant oncology and cell therapy experience", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:48.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "216749d7-3929-4862-acd1-88b549a414d3", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 6, "name": "Team", "beatId": "ad576464-d783-4af6-b425-f8685860a497", "matchId": "cc3a66c0-9acc-46c3-9d21-6e1e6cdc7cce", "beatType": { "name": "Team", "slug": "sequoia-pitch-team", "status": "active", "canonId": "019dd9b8-23c9-746f-aaf9-2f5d83892cf3", "version": 1, "description": null }, "evidence": "Slides 6-7 present team information", "position": 4, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 7, "type": "setup", "title": "The slide is split into two sections: individual board member profiles and a grid of investor logos.", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 12, "componentCount": 3, "textChars": 80, "nDataPoints": 0, "notes": "The slide is split into two sections: individual board member profiles and a grid of investor logos.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:52.111+00", "seconds": 5.143, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/7", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-7", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.55, "x": 0.08, "y": 0.18 }, "kind": "image", "text": "Board member photos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.111+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fccb2537-80d3-4670-8e1e-622dca181c16", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.25, "x": 0.73, "y": 0.0018 }, "kind": "image", "text": "Investor logos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.111+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1aa578b9-b271-4a93-80a2-864841ccf0d7", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.45, "x": 0.048, "y": 0.098 }, "kind": "title", "text": "Highly engaged board of directors and investors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.111+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5b6b8ae1-8769-48dd-a0b2-9fef6e156dcf", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 6, "name": "Team", "beatId": "ad576464-d783-4af6-b425-f8685860a497", "matchId": "cc3a66c0-9acc-46c3-9d21-6e1e6cdc7cce", "beatType": { "name": "Team", "slug": "sequoia-pitch-team", "status": "active", "canonId": "019dd9b8-23c9-746f-aaf9-2f5d83892cf3", "version": 1, "description": null }, "evidence": "Slides 6-7 present team information", "position": 4, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 8, "type": "resolution", "title": "The chart uses a Gantt-style visualization to represent clinical trial phases for different indications.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 5, "textChars": 550, "nDataPoints": 4, "notes": "The chart uses a Gantt-style visualization to represent clinical trial phases for different indications.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:51.419+00", "seconds": 4.352, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/8", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-8", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.4, "x": 0.05, "y": 0.16 }, "kind": "callout", "text": "Potentially pivotal lead product candidate CRG-022", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.419+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aa39e39f-fdc6-49dc-962e-32a74c366ffc", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.4, "x": 0.3, "y": 0.35 }, "kind": "chart", "text": "Gantt-style bars representing clinical development stages", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.419+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2cf00fcc-51f5-42c0-a4c9-52a9e7172e9d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.9 }, "kind": "source-note", "text": "(1) Based on data from the Phase 1 clinical trial conducted by Stanford and our ongoing Phase 2 clinical trial in R/R LBCL - post CD19 CAR T, we intend to discuss with the FDA initiation of a Phase 2 program in LBCL - CAR T naïve without completing earlier clinical trials in LBCL - CAR T naïve patients", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.419+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8bc3e5bb-20b3-492e-8fea-db620a17c5ff", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.9, "x": 0.05, "y": 0.27 }, "kind": "table", "text": "Pipeline table showing Program, Target, Indication, and Stage of Development", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.419+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a8e2864b-58ff-4262-b034-7c77bc8ea44b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "Pipeline of transformative CAR T-cell therapies to deliver cures", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.419+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "52a4863c-ab6c-408d-8d23-ae0d5c1dea65", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "d7ac9648-b925-4cca-a37d-d83b84ff4495", "evidence": "Pipeline development stages visualized as horizontal bars over time/phase", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:51.419+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 9, "type": "resolution", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "dense", "densityScore": 50, "componentCount": 4, "textChars": 527, "nDataPoints": 3, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:52.05+00", "seconds": 4.83, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/9", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-9", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.5, "x": 0.08, "y": 0.25 }, "kind": "chart", "text": "Projected Autologous CAR T Revenue in DLBCL", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.05+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "968e5203-a37e-40cf-aedb-5eb5cd1063bd", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.3, "x": 0.65, "y": 0.25 }, "kind": "list", "text": "Autologous CD19 CAR T-cell therapies to potentially become Standard of Care for relapsed / refractory Large B-Cell Lymphoma (R/R LBCL). Recent approvals in earlier lines of therapy and additional geographies anticipated to continue to fuel growth. Patient access broadening as more treatment centers offer CAR T and manufacturing challenges are addressed.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.05+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e4de6fcc-f58c-4f3d-bf7c-6ce19bcfb49e", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.35, "x": 0.05, "y": 0.92 }, "kind": "source-note", "text": "Source: Clarivate Disease and Landscape Forecasting (NHL, CLL) 2022; US/EU4/UK", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.05+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ee1e3a1c-1e36-411e-a0fd-34318e71f43c", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "CD19 CAR T-cell therapy: transformative and growing", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.05+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d2f7b885-371d-43c5-9803-2df99a06c297", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 9, "name": "Market Size", "beatId": "90b278ba-14fd-46df-ab28-dbf89276c85e", "matchId": "cc3a66c0-9acc-46c3-9d21-6e1e6cdc7cce", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "Slide 9 presents market sizing information", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "tension", "title": "The slide uses a Kaplan-Meier curve to visually demonstrate the 'problem' (rapid progression) and a callout box to quantify the market opportunity.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 4, "textChars": 642, "nDataPoints": 3, "notes": "The slide uses a Kaplan-Meier curve to visually demonstrate the 'problem' (rapid progression) and a callout box to quantify the market opportunity.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:56.761+00", "seconds": 9.134, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/10", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-10", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.6, "x": 0.05, "y": 0.25 }, "kind": "chart", "text": "Progression-free survival curve", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:56.761+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ecd47784-6839-4efd-8be9-b83cabb06430", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.3, "x": 0.65, "y": 0.25 }, "kind": "list", "text": "~60% of LBCL patients were observed to not achieve a durable response with CD19 CAR T-cell therapy. High unmet need with no standard of care for post CD19 CAR T patients and poor survival outcomes. By 2030, approximately 7,600 patients expected to need treatment.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:56.761+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "834a850e-bd5e-4e34-8c06-8cfcfc6f3287", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.05, "y": 0.9 }, "kind": "source-note", "text": "Source: Five-year follow-up of ZUMA-1 trial; (1) N Engl J Med 2017;377:2531-44 DOI: 10.1056/NEJMoa1707447; (2) Clarivate Disease and Landscape Forecasting (NHL, CLL) 2023; US/EU4/UK and CARGO company analysis", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:56.761+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e43dbaa2-3a74-4003-8c70-c9fe96d1b11d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "For patients whose disease R/R to CD19 CAR T-cell therapy, lead product candidate CRG-022 could address a significant and growing unmet need", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:56.761+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "959d4fc2-ad47-4cc4-8861-2e640e6f04fc", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "62e11845-861c-4c0e-a84a-4a131fb98c5c", "evidence": "Frames the current poor outcome (before) as the problem to be solved by the candidate (after).", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:56.761+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "before-after-framing" } ], "arcBeats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Problem", "beatId": "a9f20cbe-143f-496d-bc90-e53c6de8c8f4", "matchId": "cc3a66c0-9acc-46c3-9d21-6e1e6cdc7cce", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slide 10 presents the problem statement", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 15, "from": 10, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1e639289-7657-46f8-9306-fe7898bf6a06", "evidence": "The loop is opened on slide 10 and closed on slides 12-15", "position": 0, "objective": "What is the cost of not addressing the unmet need for LBCL patients whose disease is R/R to CD19 CAR T-cell therapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.138718+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "setup", "title": "The slide features a stylized 3D rendering of a cell, likely representing the therapeutic target or mechanism of action.", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 2, "componentCount": 2, "textChars": 7, "nDataPoints": 0, "notes": "The slide features a stylized 3D rendering of a cell, likely representing the therapeutic target or mechanism of action.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:50.055+00", "seconds": 2.37, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/11", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-11", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.144, "w": 0.453, "x": 0.5, "y": 0.428 }, "kind": "callout", "text": "CRG-022", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.055+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "38e943eb-b1eb-41db-9793-0002046d885e", "parentComponentId": null }, { "bbox": { "h": 0.544, "w": 0.293, "x": 0.117, "y": 0.228 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.055+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2ba141cd-8716-4846-a4f9-ad1fa3ad23b6", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 15, "from": 10, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1e639289-7657-46f8-9306-fe7898bf6a06", "evidence": "The loop is opened on slide 10 and closed on slides 12-15", "position": 0, "objective": "What is the cost of not addressing the unmet need for LBCL patients whose disease is R/R to CD19 CAR T-cell therapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.138718+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "evidence", "title": "Includes Kaplan-Meier survival curves and a summary table of clinical outcomes.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 65, "componentCount": 6, "textChars": 417, "nDataPoints": 18, "notes": "Includes Kaplan-Meier survival curves and a summary table of clinical outcomes.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:50.577+00", "seconds": 2.879, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/12", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-12", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.3, "x": 0.05, "y": 0.25 }, "kind": "chart", "text": "Progression free survival (PFS)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.577+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "020b11a3-de29-4251-b296-91715d58d667", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.3, "x": 0.38, "y": 0.25 }, "kind": "chart", "text": "Overall survival (OS)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.577+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c9f8a5b7-2372-4bc8-9976-9bf16c2a8d37", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.2, "x": 0.76, "y": 0.25 }, "kind": "list", "text": "Key Takeaways: CR rate 53%, ORR rate 68%, Median OS 14.1 months, Manufacturing success 95%", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.577+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "44c73bab-5d30-4ad6-a61c-854b2e06cc72", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.05, "y": 0.9 }, "kind": "source-note", "text": "Note: As of May 3, 2023 data cutoff date. Source: Frank MJ et al. EHA 2023", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.577+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "071a5294-168a-4e20-9c58-38cb5beb86a4", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.65, "x": 0.05, "y": 0.67 }, "kind": "table", "text": "Clinical trial data table comparing DL1, DL2, and Total cohorts", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.577+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f0fb5028-e7ad-4af1-9d40-31acca0899d8", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Phase 1 results: CRG-022 demonstrated promise to be an effective therapy for LBCL patients whose disease is R/R to CD19 CAR T-cell therapy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.577+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "06eaaf98-91a3-47fe-a32d-be3baa85c84a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 15, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Traction", "beatId": "2e0a910a-dd04-43c7-b080-55652ca53d9d", "matchId": "cc3a66c0-9acc-46c3-9d21-6e1e6cdc7cce", "beatType": null, "evidence": "Slides 12-15 present traction and results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 15, "from": 10, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1e639289-7657-46f8-9306-fe7898bf6a06", "evidence": "The loop is opened on slide 10 and closed on slides 12-15", "position": 0, "objective": "What is the cost of not addressing the unmet need for LBCL patients whose disease is R/R to CD19 CAR T-cell therapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.138718+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "setup", "title": "The slide uses a process flow diagram to illustrate the clinical trial stages.", "function": "present_framework", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 4, "textChars": 825, "nDataPoints": 8, "notes": "The slide uses a process flow diagram to illustrate the clinical trial stages.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:51.248+00", "seconds": 3.487, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/13", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-13", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.65, "x": 0.04, "y": 0.35 }, "kind": "diagram", "text": "Key eligibility criteria -> Conditioning chemotherapy -> CRG-022 dose -> Follow-up period", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.248+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1913f57f-dcac-4218-ac72-0502a416f72e", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.22, "x": 0.76, "y": 0.16 }, "kind": "paragraph", "text": "Baseline Characteristics of Treated Patients (N=38)... Primary Endpoints... Key Secondary Endpoints", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.248+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4ab1f5b5-54e3-487e-ab6e-c6ec38a3132b", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.65, "x": 0.04, "y": 0.88 }, "kind": "source-note", "text": "Abbreviations: CAR19 = anti-CD19 CAR T-cell therapy; R/R = relapsed or refractory; CRG-022 = anti-CD22 CAR T-cell therapy; DL = dose level; RP2D = recommended phase 2 dose; TEAE = treatment-emergent adverse events; ORR = overall response rate; DOR = duration of response; PFS = progression free survival; OS = overall survival; ULN = upper limit of normal; Note: Response was classified according to Lugano criteria for LBCL; Source: Cheson BD, et al. J Clin Oncol. 2014; 32(27):3059-67; Lee DW, et al. Biol Blood Marrow Transplant. 2019; 25(4):625-38; Frank MJ et al. EHA 2023", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.248+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "11a80464-2ed5-41cd-8693-13050910d7dc", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.04, "y": 0.08 }, "kind": "title", "text": "Phase 1 design – Stanford study of CRG-022 CAR T in R/R LBCL", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.248+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a86b32b4-3bca-42c1-9aba-b59c8602965f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "efd709a1-b281-443f-93d4-5cc33550958a", "evidence": "Sequential flow of clinical trial stages", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:51.248+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "process" } ], "arcBeats": [ { "to": 15, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Traction", "beatId": "2e0a910a-dd04-43c7-b080-55652ca53d9d", "matchId": "cc3a66c0-9acc-46c3-9d21-6e1e6cdc7cce", "beatType": null, "evidence": "Slides 12-15 present traction and results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 15, "from": 10, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1e639289-7657-46f8-9306-fe7898bf6a06", "evidence": "The loop is opened on slide 10 and closed on slides 12-15", "position": 0, "objective": "What is the cost of not addressing the unmet need for LBCL patients whose disease is R/R to CD19 CAR T-cell therapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.138718+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 14, "type": "setup", "title": "The slide uses a comparison table to contrast clinical trial data for CRG-022 against historical benchmarks for ZUMA-1, JULIET, and TRANSCEND.", "function": "compare_peers", "rawType": "peer_benchmark", "block": null, "metadata": { "slideType": "peer_benchmark", "slideTypeCanon": { "name": "Peer benchmark", "slug": "peer_benchmark", "status": "active", "canonId": "019de52d-08f0-7158-a78d-d7b5331fefaf", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "dense", "densityScore": 58, "componentCount": 4, "textChars": 659, "nDataPoints": 32, "notes": "The slide uses a comparison table to contrast clinical trial data for CRG-022 against historical benchmarks for ZUMA-1, JULIET, and TRANSCEND.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:51.52+00", "seconds": 3.667, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/14", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-14", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.2, "x": 0.78, "y": 0.3 }, "kind": "callout", "text": "IEC-HS incidence: DL1: 7%, DL2: 33%, Total: 18%. Managed with anakinra and steroids. Real world incidence of carHLH with CD19 CARs: Peds B-ALL: 14.8%, DLBCL: 6%", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.52+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3ee5cb3c-4783-417a-8457-81459432bc5a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.04, "y": 0.9 }, "kind": "source-note", "text": "Abbreviations: IEC-HS = Immune effector cell HLH-like syndrome; carHLH = Chimeric Antigen Receptor T-Cell-Associated Hemophagocytic Lymphohistiocytosis. Source: (1) Hines et al. 2021; (2) Ahmed et al. 2020; (3) Data reported from clinical studies for each approved therapy and not from head-to-head studies with CRG-022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.52+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "23b7cb80-7f9c-4546-966f-b8e084b29740", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.75, "x": 0.04, "y": 0.23 }, "kind": "table", "text": "Cytokine Release Syndrome and Neurologic Events/ICANS data for DL1, DL2, and Total cohorts compared to ZUMA-1, JULIET, and TRANSCEND.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.52+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ee46906a-0ba0-40c1-9ba8-379778578872", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.04, "y": 0.08 }, "kind": "title", "text": "Phase 1 – CRG-022 was generally well-tolerated", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.52+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6bb29cfd-30c3-478f-a142-9bfc7ca3ca01", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "dc7f75cc-612f-4e02-a3fa-ef61433df054", "evidence": "table/data: Cytokine Release Syndrome and Neurologic Events/ICANS data for DL1, DL2, and Total cohorts compared to ZUMA-1, JULIET, and TRANSCEND.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:45:24.402836+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "458a23d7-f031-4a5b-956b-0b1593bca8a5", "evidence": "Direct comparison of clinical trial safety data against historical benchmarks for approved therapies.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:51.52+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "frameworkName": "comparison_frame" } ], "arcBeats": [ { "to": 15, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Traction", "beatId": "2e0a910a-dd04-43c7-b080-55652ca53d9d", "matchId": "cc3a66c0-9acc-46c3-9d21-6e1e6cdc7cce", "beatType": null, "evidence": "Slides 12-15 present traction and results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 15, "from": 10, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1e639289-7657-46f8-9306-fe7898bf6a06", "evidence": "The loop is opened on slide 10 and closed on slides 12-15", "position": 0, "objective": "What is the cost of not addressing the unmet need for LBCL patients whose disease is R/R to CD19 CAR T-cell therapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.138718+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 15, "type": "evidence", "title": "Kaplan-Meier survival curve shown.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 44, "componentCount": 4, "textChars": 359, "nDataPoints": 6, "notes": "Kaplan-Meier survival curve shown.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:50.353+00", "seconds": 2.5, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/15", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-15", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.45, "x": 0.15, "y": 0.28 }, "kind": "chart", "text": "Overall survival (OS) Kaplan-Meier curve", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.353+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b801e4af-0b4a-4ce3-8e01-8fd7bb208b40", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.25, "x": 0.72, "y": 0.035 }, "kind": "list", "text": "CR rate: 53%; ORR rate: 68%; CRs typically durable; Manufacturing success rate: 95%; Recommended Ph 2 Dose: 1 million CAR+ cells/kg", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.353+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ff4e71bf-ffd2-4b68-92bd-6b6a9b24bd7e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.05, "y": 0.9 }, "kind": "source-note", "text": "Note: As of May 3, 2023 data cutoff date. Source: Frank MJ et al. EHA 2023", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.353+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e31f1bac-29e7-46e3-9d42-422bf78b3312", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "CRG-022 demonstrated durable, complete responses for LBCL patients whose disease is R/R to CD19 CAR T-cell therapy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:50.353+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b1dee8dd-1c7d-41c1-9d42-2ffd77a1e2ea", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 15, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Traction", "beatId": "2e0a910a-dd04-43c7-b080-55652ca53d9d", "matchId": "cc3a66c0-9acc-46c3-9d21-6e1e6cdc7cce", "beatType": null, "evidence": "Slides 12-15 present traction and results", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 15, "from": 10, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "1e639289-7657-46f8-9306-fe7898bf6a06", "evidence": "The loop is opened on slide 10 and closed on slides 12-15", "position": 0, "objective": "What is the cost of not addressing the unmet need for LBCL patients whose disease is R/R to CD19 CAR T-cell therapy?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.138718+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 16, "type": "setup", "title": "The slide outlines the methodology for a clinical trial, specifically detailing the patient population and treatment protocol.", "function": "present_framework", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 80, "componentCount": 7, "textChars": 843, "nDataPoints": 3, "notes": "The slide outlines the methodology for a clinical trial, specifically detailing the patient population and treatment protocol.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:52.331+00", "seconds": 3.871, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/16", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-16", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.88 }, "kind": "disclaimer", "text": "Abbreviations: R/R = relapsed or refractory; FL = follicular lymphoma; PMBCL = primary mediastinal large B cell lymphoma; HGBCL = high-grade B-cell lymphoma; PET/CT = positron emission tomography / computed tomography; ORR = overall response rate; DOR = duration of response; PFS = progression free survival; OS = overall survival", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.331+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d10eb5d4-3301-48a8-940f-6e702da93546", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.2, "x": 0.73, "y": 0.2 }, "kind": "list", "text": "Endpoints: Primary (ORR per PET/CT), Secondary (ORR, CR, DOR, PFS/OS, Safety)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.331+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "88cd86c6-1ee2-480f-81a8-869d52c2e396", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.2, "x": 0.27, "y": 0.2 }, "kind": "list", "text": "Cohort 1: Prior CD19 CAR T-cell therapy (n=81); Cohort 2: Nonconforming product or dose; Cohort 3: Prior Bispecific Abs (n=20)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.331+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a4c632a9-84bf-46e3-a621-afa403cf1735", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.2, "x": 0.5, "y": 0.2 }, "kind": "list", "text": "Conditioning chemotherapy: Fludarabine 30 mg/m2 IV, Cyclophosphamide 500 mg/m2 IV, Target CRG-022 cell dose 1 x 10^6 viable CAR+ cells/kg", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.331+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b1bbd2e0-9bcb-47de-b98f-cae742e70507", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.2, "x": 0.05, "y": 0.2 }, "kind": "list", "text": "Key eligibility criteria: R/R LBCL (DLBCL, Transformed FL, PMBCL, HGBCL), CD22 expression", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.331+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "daf06c3c-49ab-40d8-98b3-d456b7f17bf2", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Potentially pivotal Phase 2 clinical trial of CRG-022 in R/R LBCL", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.331+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6aee9de8-91f2-47a9-a45d-eb6ae671f2cd", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "Currently enrolling", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.331+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "42912c23-f0a3-4c9f-8656-65abc3b0e30c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 17, "type": "setup", "title": "The table uses checkmarks to indicate which strategic principles impact specific operational metrics.", "function": "present_framework", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "balanced", "densityScore": 25, "componentCount": 3, "textChars": 295, "nDataPoints": 0, "notes": "The table uses checkmarks to indicate which strategic principles impact specific operational metrics.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:51.945+00", "seconds": 3.392, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/17", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-17", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.04, "w": 0.92, "x": 0.04, "y": 0.885 }, "kind": "paragraph", "text": "Our approach positions us to deliver predictable and reliable supply and manage COGS to ultimately lead to enhanced patient experience", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.945+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a4d63516-5a49-489d-9e03-09cfcaeae40d", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.92, "x": 0.04, "y": 0.228 }, "kind": "table", "text": "Strategic Principle, CARGO Approach, COGS, Supply, Patient Experience, Speed", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.945+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8a4375f3-e97b-44e2-9af7-063041665202", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.92, "x": 0.04, "y": 0.04 }, "kind": "title", "text": "CMC strategy incorporates learnings from first-generation autologous CAR T experience", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.945+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "656d6935-60b1-435f-9711-1dc8adbcf4b8", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "06ac952f-32e3-4966-af82-492fb6200a7f", "evidence": "Maps strategic principles to operational outcomes", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:02:51.945+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "frameworkName": "Strategic Alignment Matrix" } ], "arcBeats": [], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 18, "type": "resolution", "title": "The slide uses a biological schematic to explain the mechanism of action and key design features of the therapeutic candidate.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 5, "textChars": 379, "nDataPoints": 0, "notes": "The slide uses a biological schematic to explain the mechanism of action and key design features of the therapeutic candidate.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:51.564+00", "seconds": 2.631, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/18", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-18", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.52, "x": 0.04, "y": 0.25 }, "kind": "image", "text": "Schematic of CAR T-cell binding to a lymphoma cancer cell", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.564+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "567ad873-2b3e-42a1-86d9-e6449ad496ae", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.38, "x": 0.58, "y": 0.25 }, "kind": "list", "text": "Key Features of CD22, Binder, GGGGS Linker, and 4-1BB", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.564+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "65b8c0ba-4252-4d9b-b9f6-718c6075270f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.02, "y": 0.92 }, "kind": "source-note", "text": "Source: Ereno-Orbea J, et al (2021) J Biol Chem 297(2): 100966; Singh N, et al (2021) Nat Med 27(5):842 BioRender", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.564+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "60915ccd-7986-4c74-b816-6c12c8e502bf", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.65, "x": 0.04, "y": 0.18 }, "kind": "title", "text": "Chimeric antigen receptor (CAR) design offers differentiated functional potential", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.564+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3ea8ca1a-75db-4099-930b-af7ff179569f", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.65, "x": 0.04, "y": 0.04 }, "kind": "title", "text": "CRG-022: An autologous CAR T-cell product candidate designed to target CD22", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.564+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ac85d996-50b4-4e25-a98a-996174d69b98", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 18, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 18, "name": "Solution", "beatId": "0b7c883f-3725-4066-9502-b130398fca42", "matchId": "cc3a66c0-9acc-46c3-9d21-6e1e6cdc7cce", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slide 18 presents the solution overview", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 19, "type": "setup", "title": "Features a stylized 3D rendering of a cell, likely representing CAR-T or similar cellular therapy.", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 4, "componentCount": 2, "textChars": 28, "nDataPoints": 0, "notes": "Features a stylized 3D rendering of a cell, likely representing CAR-T or similar cellular therapy.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:51.52+00", "seconds": 2.533, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/19", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-19", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.564, "w": 0.288, "x": 0.118, "y": 0.218 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.52+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f1b9165c-7c22-411c-abd2-7c93512462a8", "parentComponentId": null }, { "bbox": { "h": 0.16, "w": 0.35, "x": 0.5, "y": 0.42 }, "kind": "title", "text": "Pipeline & platform overview", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.52+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5202310c-cb7e-4696-8467-b077d14aedcf", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 20, "type": "resolution", "title": "The slide uses a problem-solution mapping framework to explain the therapeutic approach.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 36, "componentCount": 3, "textChars": 514, "nDataPoints": 0, "notes": "The slide uses a problem-solution mapping framework to explain the therapeutic approach.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:51.706+00", "seconds": 2.699, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/20", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-20", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.9, "x": 0.05, "y": 0.48 }, "kind": "image", "text": "Visual diagrams showing T-cell and tumor cell interactions for Antigen escape, Loss of costimulation, and Lack of T-cell persistence.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.706+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1b7fc660-e34a-4f7c-9a37-eee1f04c6b4b", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.9, "x": 0.05, "y": 0.2 }, "kind": "table", "text": "Resistance mechanism: Antigen escape (e.g., CD19), Loss of costimulation (e.g., CD58), Immune rejection of product, Loss of functional persistence. Solutions: Multi-specific CAR designs, CD2 technology, Human binders, Design, lead selection and MFG", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.706+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "50d2af27-8b96-4e99-a3a3-736c2cb22d88", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "CARGO's research platforms are designed to address multiple mechanisms of resistance to improve CAR T response in lymphoma and beyond", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.706+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b2f78563-bc54-4183-bb7d-2a07c267224e", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "e12bdec2-c728-4c7a-8157-6f2ac5442592", "evidence": "Table explicitly links resistance mechanisms to technological solutions.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:51.706+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "frameworkName": "problem-solution-mapping" } ], "arcBeats": [], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 21, "type": "tension", "title": "The slide uses a biological mechanism diagram, a Kaplan-Meier survival curve, and IHC images to demonstrate the clinical impact of CD58 loss.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 7, "textChars": 684, "nDataPoints": 2, "notes": "The slide uses a biological mechanism diagram, a Kaplan-Meier survival curve, and IHC images to demonstrate the clinical impact of CD58 loss.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:52.229+00", "seconds": 3.09, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/21", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-21", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.28, "x": 0.38, "y": 0.25 }, "kind": "chart", "text": "Axi-Cel Treated LBCL", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.229+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7ece08aa-ab7d-459e-abee-8446ec172659", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.3, "x": 0.05, "y": 0.25 }, "kind": "diagram", "text": "Loss of costimulation can lead to reduced tumor killing from CAR T cells", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.229+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f382773d-53a9-45b5-9047-5625b15b4063", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.25, "x": 0.7, "y": 0.25 }, "kind": "image", "text": "CD58 pre-treatment and CD58 at relapse IHC images", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.229+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d2eea0aa-65ef-4e26-9864-7d3bb41ee2d9", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.18 }, "kind": "paragraph", "text": "Approximately 25% of patients LBCL patients treated with CD19 CAR T have mutated or absent CD58", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.229+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c0660234-9ed1-4eba-a175-e3ba866a930b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.85 }, "kind": "paragraph", "text": "CD58 loss has also been observed across lymphoma subtypes and in other tumor types (myeloma, AML, colon CA, melanoma)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.229+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c911acce-b900-4789-aa4a-82de79ab10bf", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.92 }, "kind": "source-note", "text": "Source: Majzner ASH Annual Meeting, 2020; Yan, X., et. Al., Blood Advances, 2022; Younes et. Al., Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance, Mod Pathol. 2023 Jun 28;36(10):1002568", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.229+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cd58c29f-9c81-4c1c-a29d-579dcdb10d2f", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Aberrant CD58 expression in lymphoma associates with poor CD19 CAR T outcomes", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.229+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c7595be-26d0-4344-aff2-05cc10412ed3", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 22, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 2, "componentCount": 2, "textChars": 7, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:52.472+00", "seconds": 3.313, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/22", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-22", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.146, "w": 0.452, "x": 0.5, "y": 0.427 }, "kind": "callout", "text": "CRG-023", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.472+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f8b2cc1e-417a-464d-80e8-a681be7b2d09", "parentComponentId": null }, { "bbox": { "h": 0.54, "w": 0.294, "x": 0.117, "y": 0.23 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.472+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8fa526bb-8125-4d59-a18a-5112800d1c38", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 23, "type": "resolution", "title": "The slide uses a funnel diagram to represent the screening process and bar charts to demonstrate specificity across CD19, CD20, and CD22 targets.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 58, "componentCount": 4, "textChars": 688, "nDataPoints": 15, "notes": "The slide uses a funnel diagram to represent the screening process and bar charts to demonstrate specificity across CD19, CD20, and CD22 targets.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:51.859+00", "seconds": 2.665, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/23", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-23", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.45, "x": 0.52, "y": 0.63 }, "kind": "chart", "text": "CD19 specificity; CD20 specificity; CD22 specificity", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e4b0b279-57bd-40a2-8eeb-7f22e7f971dc", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.45, "x": 0.52, "y": 0.18 }, "kind": "diagram", "text": "Screening funnel: Molecular design & cloning; CAR expression / antigen binding; Memory & activation phenotype; Cytokines & cell killing; Serial killing; In vivo activity", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": "funnel", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "291be56a-166f-4b4d-afe1-b3c82455c45b", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.45, "x": 0.04, "y": 0.245 }, "kind": "diagram", "text": "Obtain novel, human binders from antibody discovery campaigns for both CD19 and CD20; Screen top 30 CD19 and CD20 binders as mono-specific CARs; Screen permutations of top 5 CD19 and CD20 binders as bi- and tri-specific CARs to determine compatibility; Screen top CD19 and CD20 binders for off-target binding; Optimize plasmid of CRG-023 for titer, expression and activity", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3ac087c5-92ee-4962-adb5-3eeb4c71c7bd", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.04, "y": 0.05 }, "kind": "title", "text": "CRG-023 is a CD19, CD20, CD22 CAR T-cell product candidate that incorporates CD2 co-stimulation", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:51.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c74238a5-f286-4502-839b-6a82721bedf6", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "574ea350-b439-431e-a4cc-3a462715cb50", "evidence": "Screening funnel diagram", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:02:51.859+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "frameworkName": "funnel" } ], "arcBeats": [], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 24, "type": "evidence", "title": "Data shows bioluminescent flux over time; CRG-023 consistently reduces tumor burden to baseline.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 57, "componentCount": 5, "textChars": 485, "nDataPoints": 2, "notes": "Data shows bioluminescent flux over time; CRG-023 consistently reduces tumor burden to baseline.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:52.426+00", "seconds": 2.858, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/24", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-24", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.4, "x": 0.55, "y": 0.75 }, "kind": "callout", "text": "CRG-023 was observed to reduce tumor burden to background levels while monospecific CAR T cells were only partially effective in an antigen loss model", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.426+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "037a148b-1c05-4b3d-a64e-db189d22a2ce", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.05, "y": 0.75 }, "kind": "callout", "text": "CRG-023 was observed to reduce tumor burden to background levels while monospecific CAR T cells were only partially effective in a three-antigen model", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.426+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fa9dc2f6-64f6-4f97-a1a8-53074d1dc1ac", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.4, "x": 0.05, "y": 0.25 }, "kind": "chart", "text": "B cell tumor mouse model efficacy chart", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.426+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5e21c232-17e3-42c6-80d4-72812b1b190b", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.4, "x": 0.55, "y": 0.25 }, "kind": "chart", "text": "1:1:1 Raji CD19KO:CD20KO:CD22KO efficacy chart", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.426+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7a67d412-8c1b-41bf-a4ef-9949462a8c4d", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "CRG-023 has increased in vivo activity in mouse tumor models with all antigens and with antigen loss", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.426+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9c665c1d-7969-405b-86b8-78768e72f9de", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 25, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 5, "componentCount": 2, "textChars": 43, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:52.073+00", "seconds": 2.313, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/25", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-25", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.3, "x": 0.118, "y": 0.25 }, "kind": "image", "text": "3D rendering of a cell", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.073+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b6c4a42d-c2f1-47a6-9e53-e4a44c540e4c", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.45, "x": 0.5, "y": 0.425 }, "kind": "title", "text": "Competitive landscape", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.073+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "253ac3a0-eee3-49a4-87a7-4a7cb540dc99", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 26, "type": "setup", "title": "The slide uses a matrix structure to categorize therapies by modality and development stage, highlighting CARGO's specific positioning.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 4, "textChars": 268, "nDataPoints": 12, "notes": "The slide uses a matrix structure to categorize therapies by modality and development stage, highlighting CARGO's specific positioning.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:53.495+00", "seconds": 3.478, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/26", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-26", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.25, "x": 0.7, "y": 0.9 }, "kind": "legend", "text": "CD19, CD20, CD22, Dual target/Other", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:53.495+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "36421052-8f2b-4230-9d16-1e9e3a9bb398", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.9, "x": 0.05, "y": 0.18 }, "kind": "table", "text": "Matrix of therapies by modality (Auto, Allo, Bispecifics) and phase (1, 2, 3, Approved)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:53.495+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8ee991a5-1e1b-4559-80ca-70f9928ef85e", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.6, "x": 0.05, "y": 0.12 }, "kind": "title", "text": "Few competitors are specifically pursuing patients with LBCL R/R to CD19 CAR T", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:53.495+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6aef2ac5-48b8-4b78-b35c-e38c2c8fbb87", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "CARGO is uniquely positioned in a competitive cell therapy landscape", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:53.495+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ba26607e-5062-47a7-841f-7b28c951caa2", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "bdc83d46-4efb-40ff-972a-fc4639626464", "evidence": "Matrix of therapies by modality (Auto, Allo, Bispecifics) and phase (1, 2, 3, Approved)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:44:53.691873+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "3eb4066a-bb9b-4270-9a8e-8c7433cf5973", "evidence": "The slide organizes data into a grid based on modality and clinical phase.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:02:53.495+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "frameworkName": "matrix-nxn" } ], "arcBeats": [], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 27, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 4, "componentCount": 2, "textChars": 32, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:52.813+00", "seconds": 2.592, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/27", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-27", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.54, "w": 0.31, "x": 0.11, "y": 0.23 }, "kind": "image", "text": "3D rendering of a cell", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.813+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "53839fc0-796e-4763-901a-c798764a1946", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.45, "x": 0.5, "y": 0.42 }, "kind": "title", "text": "Conclusion", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.813+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b099c7bc-1c79-40be-bafe-3e66a2cd40c8", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 28, "type": "setup", "title": "Includes investor logos, financial metrics, and a timeline of clinical milestones.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 66, "componentCount": 6, "textChars": 518, "nDataPoints": 3, "notes": "Includes investor logos, financial metrics, and a timeline of clinical milestones.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:53.097+00", "seconds": 2.845, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/28", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-28", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.3, "x": 0.05, "y": 0.91 }, "kind": "disclaimer", "text": "*Includes Series A Tranche 3. Note: As of May 3, 2023 data cutoff date", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:53.097+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0c888606-4f73-45bc-a81a-7a1018cc4288", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.45, "x": 0.52, "y": 0.215 }, "kind": "image", "text": "Investor logos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:53.097+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0b3f088d-56fb-4c10-839e-8b9f44f43b50", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.45, "x": 0.05, "y": 0.215 }, "kind": "list", "text": "Positive Phase 1 results in CD19 CAR T R/R LBCL; Initiated Phase 2 clinical trial; FDA Breakthrough Therapy Designation; Proprietary cell engineering platform; Seasoned leadership team", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:53.097+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "081232fd-44ff-4d07-8d07-ab970ae2749a", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.45, "x": 0.05, "y": 0.62 }, "kind": "list", "text": "Post-money valuation: $317mm; Cash runway into Q2 2024; Use of proceeds for multiple catalysts", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:53.097+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b556c0a8-512b-4d6d-9e02-538480511565", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.45, "x": 0.52, "y": 0.62 }, "kind": "table", "text": "Initiation of Phase 2: August 2023; Interim Phase 2 results: 2025 (expected)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:53.097+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dc0054ba-d1ec-4e17-8e8e-8d4dd4be2d3a", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "CARGO – focused on developing and delivering potentially curative cell therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:53.097+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6e4635dd-a11a-4f8b-a135-4f5e28bb07f9", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "5a6e40f7-9297-435d-8179-e16d50eab4ab", "evidence": "CARGO – focused on developing and delivering potentially curative cell therapies", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:44:53.796678+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 28, "from": 4, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97", "evidence": "The loop is opened on slide 4 and closed on slide 28", "position": 1, "objective": "Why does CARGO Therapeutics exist? What is the company's vision?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:43:26.181962+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 29, "type": "setup", "function": "summarize", "rawType": "closing_ask", "block": null, "metadata": { "slideType": "closing_ask", "slideTypeCanon": { "name": "Closing ask", "slug": "closing_ask", "status": "active", "canonId": "019de52d-0aa4-750f-8aa1-8d622dd99f5c", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "sparse", "densityScore": 4, "componentCount": 2, "textChars": 27, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:02:52.632+00", "seconds": 2.162, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/29", "deck": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05", "deckAnchor": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-29", "deckJson": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json" }, "components": [ { "bbox": { "h": 0.031, "w": 0.101, "x": 0.047, "y": 0.954 }, "kind": "image", "text": "CARGO THERAPEUTICS", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.632+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f41693c7-585d-4485-8059-d96110165d57", "parentComponentId": null }, { "bbox": { "h": 0.083, "w": 0.254, "x": 0.373, "y": 0.458 }, "kind": "title", "text": "Thank you", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:02:52.632+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c017d7c8-82b2-4934-9297-3cb50726b077", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Storytelling: the closing ask", "slug": "closing-ask", "status": "active", "bestFor": null, "canonId": "019df269-24e0-70ab-8dd9-983832c1c665", "version": 1, "bodyDocId": "019df269-24bc-7554-b88d-245127606b8d", "description": "The single most important slide in the deck — after the cover. The final", "familyLabel": "narrative-block", "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "agent": "storyteller", "layer": "slide", "agents": [ "storyteller" ], "matchId": "12cfb54e-21c5-4487-bdb7-257c4696e4ad", "evidence": "Thank you", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:44:53.896346+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 10, "to": 10, "label": "Problem", "description": "Slide 10 presents the problem statement" }, { "from": 18, "to": 18, "label": "Solution", "description": "Slide 18 presents the solution overview" }, { "from": 9, "to": 9, "label": "Market Size", "description": "Slide 9 presents market sizing information" }, { "from": 12, "to": 15, "label": "Traction", "description": "Slides 12-15 present traction and results" }, { "from": 6, "to": 7, "label": "Team", "description": "Slides 6-7 present team information" } ], "loops": [ { "from": 10, "to": 15, "label": "Cost Of Inaction", "description": "What is the cost of not addressing the unmet need for LBCL patients whose disease is R/R to CD19 CAR T-cell therapy?" }, { "from": 4, "to": 28, "label": "Golden Circle", "description": "Why does CARGO Therapeutics exist? What is the company's vision?" } ] }